- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00938002
Study to Determine Quicker Methods of Diagnosing Pneumonia Caused by a Breathing Machine in Critically Ill Patients
December 22, 2019 updated by: Ivor Douglas, Denver Health and Hospital Authority
Rapid Bacterial Identification and Antibiotic Resistance Testing in Critically Ill Adults at Risk for Ventilator Acquired Pneumonia (VAP).
Critically ill patients on a breathing machine are at risk of developing a type of pneumonia called Ventilator Acquired Pneumonia (VAP).
The purpose of this study is to determine if regular lung rinses sent for microbiological testing can reduce the time to diagnose VAP.
The study also plans to test the accuracy and speed of a new technology, using multiplexed automated digital microscopy, to identify the germs causing the VAP.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Ventilator-associated pneumonia (VAP) is a common, life-threatening hospital-acquired infectious complication of prolonged mechanical ventilation (MV).
Despite aggressive efforts to prevent VAP, rates remain high because clinical diagnosis is imprecise and microbiological diagnosis is frequently delayed.
Diagnosis of VAP depends on clinical signs as well as microbiologic evidence from Bronchioalveolar Lavage (BAL) cultures.
Ordinarily, these cultures are only ordered after the patient presents with clinical signs and symptoms of VAP, which can significantly delay diagnosis and effective therapy.
This research proposes to implement additional surveillance BAL cultures in order to reduce the time to diagnosis of VAP in mechanically ventilated critically ill adults.
To further reduce the time to diagnosis of VAP, this research aims to test part of the BAL cultures using a novel flowcell/surface-capture device that allows direct from specimen visualization of bacteria using multiplexed automated digital microscopy (BACcel™) for rapid bacterial identification and antibiotic resistance testing.
Additionally, molecular assays of the BAL sample will characterize lower respiratory tract antimicrobial peptide host-innate immune molecule and local anti-oxidant defenses in mechanically ventilated adults at risk for VAP.
Study Type
Observational
Enrollment (Actual)
37
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80204
- Denver Health Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Critically ill ventilated patients
Description
Inclusion Criteria:
- Written, informed consent (by surrogate if unconscious or if altered mental status)
- ≥ 18 years old
- Admission to a Medical Intensive care unit
- Orally/nasally intubated, evaluable within 72 h of initial intubation
- Expected to remain mechanically ventilated for at least 48 h after the first study procedure
Exclusion Criteria:
- Previously documented cystic fibrosis
- Diffuse bronchiectasis
- Severe or massive hemoptysis
- Presence of an advanced directive to withhold life-sustaining treatment
- Morbid state or expected to survive less than 14 days because of an advanced co-morbid medical condition
- Participation in a clinical trial of any unlicensed drug or device within 30 days
- Pregnant or Nursing
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Reduction in time to diagnosis and treatment of VAP in an at risk population
Time Frame: 30 days
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Ivor S Douglas, MD, Denver Health and Hospital Authority
- Principal Investigator: Connie S Price, MD, Denver Health and Hospital Authority
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2009
Primary Completion (Actual)
September 19, 2019
Study Completion (Actual)
September 19, 2019
Study Registration Dates
First Submitted
July 10, 2009
First Submitted That Met QC Criteria
July 10, 2009
First Posted (Estimate)
July 13, 2009
Study Record Updates
Last Update Posted (Actual)
December 24, 2019
Last Update Submitted That Met QC Criteria
December 22, 2019
Last Verified
December 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 09-0321
- UL1RR025780 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ventilator Acquired Pneumonia
-
Melinta Therapeutics, Inc.WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
Nantes University HospitalSociété Française d'Anesthésie et de RéanimationCompletedPneumonia | Sepsis | Ventilator-Associated Pneumonia | Hospital Acquired PneumoniaFrance
-
University Medical Centre LjubljanaUniversity of Ljubljana, Faculty of MedicineUnknownCommunity Acquired Pneumonia | Ventilator Associated Pneumonia | Hospital Acquired PneumoniaSlovenia
-
Assistance Publique - Hôpitaux de ParisRecruitingMechanical Ventilation | Ventilator-acquired Pneumonia | Tracheal Intubation | Intubation -Related Tracheal LesionsFrance
-
Angulus, LLCNational Heart, Lung, and Blood Institute (NHLBI); Albert Einstein College... and other collaboratorsCompletedHospital-acquired Pneumonia | Ventilator Associated Pneumonia | Hospital Acquired Condition | Ventilator Adverse Event | Recumbency | Head-of-bedUnited States
-
Avicenna Military HospitalCompletedHospital-acquired Pneumonia | Ventilator Associated Pneumonia | Community-acquired PneumoniaMorocco
-
PfizerRecruitingHospital Acquired Pneumonia | Complicated Intra Abdominal Infections | Ventilator Acquired PneumoniaChina
-
University Hospital OlomoucCompletedVentilator-Associated Pneumonia
-
Yale UniversityNational Heart, Lung, and Blood Institute (NHLBI); Oregon Health and Science...CompletedVentilator-acquired PneumoniaUnited States
-
Methodist Health SystemCompletedHospital-acquired Pneumonia | Ventilator-associated PneumoniaUnited States
Clinical Trials on Acceler8 Pheno
-
Accelerate Diagnostics, Inc.Withdrawn